A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients

NCT00089492 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Optimized Background ARVs
DRUG: enfuvirtide [Fuzeon]
DRUG: enfuvirtide [Fuzeon]

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]